| Biotinylated Human HBV (HLA-A*02:01) Protein (LTP10126) |
| LTP10126 |
| 100ug |
|
$609 In stock |
| Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). |
| Recombinant Biotinylated Human HBV(HLA-A*02:01) Protein is expressed from Expi293 with His tag and Avi tag at the C-terminalIt contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and FLLTRILTI peptide. |
| HBV (HLA-A*02:01) |
| Human |
| A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide |
| Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide |
| The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on the Tris-Bis PAGE result. |
| 0 |
| C-His-Avi |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| |